Healthcare Services

Non-Insulin Therapies For Diabetes Market 2026–2030: Forecasting Business Opportunities Ahead

February 27, 2026April 15, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the non-insulin therapies for diabetes market from 2026–2035 with trusted insights from The Business Research Company

What market expansion outlook does the Non-Insulin Therapies For Diabetes Market show for the 2026–2030 period?

The non-insulin therapies for diabetes market size has experienced strong growth in recent years. It is projected to expand from $21.21 billion in 2025 to $22.59 billion in 2026, at a compound annual growth rate (CAGR) of 6.5%. Historically, this market expansion can be ascribed to factors such as the high prevalence of type 2 diabetes, the continued reliance on oral hypoglycemic agents, challenges with patient adherence to insulin therapy, the expansion of hospital and retail pharmacy distribution networks, and the introduction of various new drug classes.

The market for non-insulin therapies for diabetes is projected to experience substantial growth in the coming years. It is expected to expand to $28.39 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.9%. This anticipated growth throughout the forecast period stems from factors such as the increased adoption of non-insulin drug combinations, a rise in the utilization of GLP-1 and SGLT2 inhibitors, the expansion of online pharmacy channels, the evolution of personalized and precision medicine approaches, and the advancement in integrating digital health and remote monitoring. Significant trends during this period include a growing embrace of personalized diabetes management, the increasing application of AI-driven glucose monitoring systems, the broadening integration of telemedicine-linked therapy solutions, the expanding implementation of data-driven clinical decision support, and the progressive deployment of connected devices for remote patient care.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16494&type=smp

What Drivers Are Shaping The Development Of The Non-Insulin Therapies For Diabetes Market?

The rising occurrence of diabetes is anticipated to propel the growth of non-insulin therapies for the diabetes market going forward. Diabetes is a chronic medical condition characterized by elevated blood glucose (sugar) levels, occurring when the body either cannot produce enough insulin or effectively use the insulin it makes. The number of diabetes cases is increasing due to sedentary lifestyles, unhealthy diets, genetic predisposition, aging populations, obesity, ethnicity, lack of awareness, limited access to healthcare, and environmental factors. Non-insulin therapies for diabetes help manage the condition by improving insulin sensitivity, reducing glucose production in the liver, increasing glucose uptake in muscle cells, and enhancing overall glycemic control. For instance, in March 2024, according to the Office for Health Improvement & Disparities, a UK-based government agency, the GP-recorded prevalence of type 2 diabetes among adults aged 17 and over rose to 7.0%, up from 6.8% in March 2023. Therefore, the increase in the prevalence of diabetes is driving the growth of non-insulin therapies for the diabetes market.

Which Segments Are Contributing To The Growth Of The Non-Insulin Therapies For Diabetes Market?

The non-insulin therapies for diabetes market covered in this report is segmented –

1) By Type: Biguanides, Sulfonylureas, Thiazolidinediones (TZDs), DPP 4 Inhibitors, GLP 1 Analogs Or Agonists, SGLT2 Inhibitors

2) By Route Of Administration: Oral, Injectable

3) By Application: Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End User: Hospitals Or Clinics, Homecare Or Patients, Other End-Users

Subsegments:

1) By Biguanides: Metformin, Combination Of Metformin With Other Drugs

2) By Sulfonylureas: Glimepiride, Glipizide, Glyburide

3) By Thiazolidinediones (TZDs): Pioglitazone, Rosiglitazone

4) By DPP 4 Inhibitors: Sitagliptin, Saxagliptin, Linagliptin

5) By GLP 1 Analogs Or Agonists: Exenatide, Liraglutide, Dulaglutide

6) By SGLT2 Inhibitors: Canagliflozin, Dapagliflozin, Empagliflozin

Which Market Trends Are Opening Growth Opportunities In The Non-Insulin Therapies For Diabetes Market?

Major companies operating in the non-insulin therapies for diabetes market are focusing on developing advanced solutions, such as non-insulin GLP-1 receptor agonist, with the aim of expanding treatment options, improving glycemic control, and strengthening their competitive position in the diabetes and obesity care landscape. A non-insulin GLP-1 receptor agonist launch refers to the introduction of therapies that target GLP-1 receptors to support blood glucose regulation and weight reduction independently of insulin. For instance, in March 2025, Eli Lilly and Company, a US-based pharmaceutical company specializing in diabetes and metabolic therapies, introduced Mounjaro (tirzepatide) in India, subsequent to approval from the Central Drugs Standard Control Organisation. Designed as a dual GIP and GLP-1 receptor agonist, Mounjaro addresses key challenges in type 2 diabetes and obesity management by offering once-weekly subcutaneous administration, enhancing glycemic control, reducing appetite, slowing gastric emptying, and supporting significant weight reduction, with dosing options commencing at 2.5 mg and 5 mg to improve patient adherence and long-term outcomes.

Who Are The Prominent Global Companies Shaping The Non-Insulin Therapies For Diabetes Market Landscape?

Major companies operating in the non-insulin therapies for diabetes market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi, The Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Les Servier Laboratories, Sumitomo Dainippon Pharma Co. Ltd., Jiangsu Hansoh Pharmaceutical Group Co. Ltd., Uni-Bio Science Group Ltd., Intarcia Therapeutics, Janssen Pharmaceuticals, Boan Biotech, SatRx LLC

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/non-insulin-therapies-for-diabetes-global-market-report

Which Region Is Projected To Lead The Non-Insulin Therapies For Diabetes Market During The Forecast Period?

North America was the largest region in the non-insulin therapies for diabetes market in 2025. The regions covered in the non-insulin therapies for diabetes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Non-Insulin Therapies For Diabetes Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=16494&type=smp

Browse Through More Reports Similar to the Global Non-Insulin Therapies For Diabetes Market 2026, By The Business Research Company

Antidiabetics Market Report 2026

https://www.thebusinessresearchcompany.com/report/antidiabetics-global-market-report

Non Injectable Insulin Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-injectable-insulin-global-market-report

Oem Insulation Market Report 2026

https://www.thebusinessresearchcompany.com/report/oem-insulation-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795